The National Institute for Health and Welfare recommends PrEP for people with a high risk for HIV transmission. As a part of a comprehensive prevention program, PrEP has reduced new HIV transmissions in all countries where it is available. When used correctly, PrEP provides up to 99% reduction in HIV risk. The Finnish national guidelines are released today, 17 April 2019.
TAG and PrEP4All sent this letter to Dr. Debra Birnkrant of the FDA, outlining and expressing our serious concerns about Gilead’s supplemental New Drug Application for Descovy (FTC/TAF) as HIV-1 preexposure prophylaxis (PrEP). There are several specific recommendations in the letter for this approval process, including recomending that the FDA convene a public meeting of the Antiviral Drug Advisory Committee.
Analysis of men who acquired HIV in the deferred arm of the
PROUD study highlights two risk factors that are far more important than any
others. “A recent history of syphilis or rectal chlamydia/gonorrhoea, or
multiple ncRAI [receptive anal intercourse without a condom] partners indicates a high
imminent risk of HIV infection,” Ellen White
In a boost to HIV prevention in the capital, London boroughs have agreed to provide over 4,000 extra places on the PrEP Impact Trial. The trial – a national programme led by NHS England in partnership with Public Health England and local authorities – supplies PrEP (an HIV prevention medicine) free of charge to individuals considered to be at high risk of exposure to HIV. The expansion, which will take place over the coming weeks, represents a 60% increase in the trial places available to Londoners. London already accounts for 7,609 trial places – a higher figure than the rest of England combined.
John Biggs, Mayor of Tower Hamlets has written to Matt Hancock the Secretary of State for health, to call for the funding of HIV treatment that could stop the spread of HIV, saving the NHS millions of pounds.
For years, the U.S. HIV prevention community has known that pre-exposure prophylaxis (PrEP) is prohibitively expensive for many patients who need it. Now, new research presented at the 2019 National HIV Prevention Conference (NHPC) in Atlanta finds that not only is PrEP expensive for individual patients, it's also not cost-effective for the health system as a whole.
Black men who have sex
with men (MSM) in London experience a unique set of motivations and barriers to
using pre-exposure prophylaxis (PrEP), according to the results of a recent
qualitative study published in Sexually
Transmitted Infections. This research was carried out by T. Charles Witzel
and colleagues at the London School of Hygiene and
A study of gay and
bisexual men diagnosed with recently acquired hepatitis C infection and treated
in three English clinics has found that 40% of them were HIV negative,
the 25th Annual Conference of the British HIV Association (BHIVA) was
told in Bournemouth this week, though all the HIV-negative men were in London.Daniel Bradshaw of
Dr. Robert Redfield, director of the Centers for Disease Control, was shouted down by activists during a speech to the AIDSWatch conference after he refused to explain why the government agency wasn’t enforcing its patent on the HIV drug Truvada.
A combination of the drugs raltegravir and lamivudine produced acceptable drug levels in both women and men, in rectal and vaginal tissues, suggesting that the two drugs could provide an effective alternative to tenofovir-based pre-exposure prophylaxis (PrEP), the 25th Annual Conference of the British HIV Association (BHIVA) heard in Bournemouth yesterday.Dr
The recent report on the first year of the implementation
of pre-exposure prophylaxis (PrEP) through the National Health Service (NHS) in Scotland concludes: “Year one has been a resounding success in terms of establishing a
new nationwide service – the first of its type in the UK and one of the first
urine test can accurately determine if a person is adherent to tenofovir-based
pre-exposure prophylaxis (PrEP), according to research presented to the recent Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle. The
test checks for antibodies to tenofovir and was tested in a trial of 30 people in Thailand who
Two studies in monkeys of experimental pre-exposure prophylaxis
(PrEP) regimens featuring the drug tenofovir alafenamide (TAF) produced differing
results when presented at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle. As a third study suggested,
the results may partly be due to the way TAF is absorbed into cells.
Whether HIV pre-exposure prophylaxis (PrEP) is effective depends
on whether people take it appropriately, at the times when they are at risk of
HIV. But we know surprisingly little about how people receiving PrEP through
health services take PrEP, in terms of whether they take it correctly, how long
they take it for, and
One question often asked about pre-exposure prophylaxis (PrEP) use is how frequently
people start PrEP while unknowingly having HIV, often because they have acquired
it so recently that they are still in the ‘window period’ when it cannot be
detected. If someone has undiagnosed HIV and takes PrEP, this can cause HIV drug
A daily pill containing the newer formulation of tenofovir
in combination with emtricitabine (Descovy)
had a comparable protective effect to the existing daily pill which
contains the older tenofovir and emtricitabine (Truvada), Dr Brad Hare of the Kaiser Permanente San Francisco
Medical Center told the Conference on Retroviruses and Opportunistic Infections
(CROI 2019) in Seattle